MAPT and Alzheimer disease: The present studies demonstrate that non-peptide small molecule ligands targeting p75NTR, a receptor upregulated in neurons vulnerable in AD, prevent Aβ-induced neuritic dystrophy and cell death, while inhibiting Aβ-induced tau phosphorylation and the activation of several key signaling intermediates, each a candidate therapeutic target in its own right.